Expedited decision on Tysabri?
FDA says it is trying to complete its review of Biogen Idec/Elan's Tysabri before the new June 28, 2006 review deadline. Natalizumab's user fee date is being extended 90 days to review changes to the drug's risk management plan. The Tysabri application is a "high priority" and FDA is "working intensively to complete review of this new information and will attempt to do so before the end of the 90-day extension period," the agency says. Re-launch of the multiple sclerosis drug is now slated for the third quarter...
You may also be interested in...
Cover Three Nutritional Brain Defense marketer agrees to pull claims suggesting the supplement beverage can protect against traumatic brain injury after a test the firm on DHA submitted as support contained considerably higher levels of the ingredient than included in the product.
The top-line data in the ultra-rare disease are also the first to demonstrate safety and efficacy of an RNAi therapy in patients six years and younger.
Bayer notes “significant headwinds" from pandemic hitting its 2020 results likely will continue in 2021, when it t expects core earnings per share slightly below 2020 levels. While noting slumping revenues across its divisions, Bayer said an exception its consumer health business.